The wave of new gene therapy could cost $12.2 billion per year, which means state governments are in for a world of hurt, financially speaking. (Jessica Karl, 10/16) The Atlantic: Is Novo Nordisk's Success Really Trouble For Denmark? Over the past couple of years, no new pharmaceutical drug—perhaps no product, period—has had such widespread impact as the diabetes medication Ozempic and the weight-loss drug Wegovy, both made by Danish company Novo Nordisk. Most obviously, the drugs have changed the lives of the millions of people who now count on them to help control their appetite. These two products have taken Novo Nordisk from a successful but second-tier drugmaker to the most valuable company in Europe. (James Surowiecki, 10/16) The Washington Post: What Is The Line Between Life And Death? Here's My Answer Where, exactly, is the line between life and death? Does the answer change if the person asking is not a philosopher but a transplant surgeon eager to save a life? Or a patient desperate for a new organ?